Author:
Shen Junjie,Wang Shuo,Dong Yongfei,Sun Hao,Wang Xichao,Tang Zaixiang
Abstract
Abstract
Background
High-dimensional omics data are increasingly utilized in clinical and public health research for disease risk prediction. Many previous sparse methods have been proposed that using prior knowledge, e.g., biological group structure information, to guide the model-building process. However, these methods are still based on a single model, offen leading to overconfident inferences and inferior generalization.
Results
We proposed a novel stacking strategy based on a non-negative spike-and-slab Lasso (nsslasso) generalized linear model (GLM) for disease risk prediction in the context of high-dimensional omics data. Briefly, we used prior biological knowledge to segment omics data into a set of sub-data. Each sub-model was trained separately using the features from the group via a proper base learner. Then, the predictions of sub-models were ensembled by a super learner using nsslasso GLM. The proposed method was compared to several competitors, such as the Lasso, grlasso, and gsslasso, using simulated data and two open-access breast cancer data. As a result, the proposed method showed robustly superior prediction performance to the optimal single-model method in high-noise simulated data and real-world data. Furthermore, compared to the traditional stacking method, the proposed nsslasso stacking method can efficiently handle redundant sub-models and identify important sub-models.
Conclusions
The proposed nsslasso method demonstrated favorable predictive accuracy, stability, and biological interpretability. Additionally, the proposed method can also be used to detect new biomarkers and key group structures.
Funder
National Natural Science Foundation of China
Priority Academic Program Development of Jiangsu Higher Education Institutions
Suzhou Science and Technology Development Plan
Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Gupta GK, Collier AL, Lee D, et al. Perspectives on triple-negative breast cancer: current treatment strategies, unmet needs, and potential targets for future therapies. Cancers. 2020;12(9):2392.
2. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013;108(3):479–85.
3. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17(9):507–22.
4. Heinze G, Wallisch C, Dunkler D. Variable selection—a review and recommendations for the practicing statistician. Biometrical J. 2018;60(3):431–49.
5. Zhang YP, Zhang XY, Cheng YT, et al. Artificial intelligence-driven radiomics study in cancer: the role of feature engineering and modeling. Mil Med Res. 2023;10(1):22.